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eripheral artery disease (PAD) is one of the major complications in patients on hemodialysis (HD). The number of patients with PAD is increasing due to increases in the number of patients on HD, the elderly population and patients with diabetic nephropathy. Surgical bypass grafting (bypass) and percutaneous transluminal angioplasty (PTA) are the 2 main interventional treatments for PAD. The advantages of surgery over than PTA were reported to be good long-term anatomical patency and clinical durability. [1] [2] [3] In contrast, balloon angioplasty was reported to have the advantages of low procedural morbidity and mortality, and a shortened hospital stay. 4,5 A recent randomized controlled trial that compared the outcomes of bypass and PTA in patients with severe limb ischemia and concluded that their outcomes were similar. 6 In HD patients, however, several studies described the outcome of dialysis patients with PAD who were treated by bypass surgery. 7-10 The survival at 1 and 2 years was in the range of 50-60% and 40-50%, respectively. The cumulative limb salvage rate and primary patency rate at 1 year were in the range of 50-80% and 50-70%, respectively. Also PTA was considered as feasible and effective in HD patients with severe PAD. 11, 12 However, these studies did not directly compare the outcomes of these 2 treatments in patients on HD, and treated years were different between these 2 groups. The primary endpoint of this retrospective study was to compare the outcomes between HD and non-HD patients, and the secondary endpoint of this study was to reveal the characteristics of PAD treatments in HD patients by directly determining the outcome associated with bypass or PTA between Characteristics of Revascularization for ASO in HD patients who were or were not receiving HD.
Methods
The study population included 231 symptomatic patients with chronic limb ischemia who underwent bypass or PTA at our hospital between 1999 and 2006. Patients who could not achieve clinical success (12 patients in PTA and 1 patient in bypass), who had been treated with in-stent restenosis (10 patients), had a past history (within 3 months) of angioplasty (16 patients), had had a scheduled amputation after the procedure (2 patients in PTA), had symptomatic advanced malignancy (1 patient in PTA), could not be followed up after discharge (4 patients in PTA and 2 patients in bypass), and who were considered inadequate to follow up (2 patients in PTA and 1 patient in bypass) were excluded from this study. As a result, 180 symptomatic patients with chronic limb ischemia who underwent bypass or PTA were included in this study. The primary endpoint of this study was amputation of the ischemic leg or death, and the secondary endpoint was occlusion after treatment. We compared these outcomes between HD and non-HD patients, and then determined outcomes associated with bypass or PTA between them. Whether to perform bypass or PTA was considered according to the Trans Atlantic Inter-Society Consensus (TASC) criteria 13,14 after discussion among cardiovascular specialists.
Clinical success was defined by the absence of residual obstructions after treatment. 12 All subjects were diagnosed with limb ischemia by clinical symptoms, angiographic examinations and the ankle-brachial pressure index (ABI) (form PWV/ABI; Omron Colin, Tokyo, Japan). Patients' previous histories were examined by using clinical records. A history of ischemic heart disease was defined as a history of angina pectoris or myocardial infarction. Renal function of the patients who did not receive hemodialysis was calculated by using an estimated glomerular filtration rate (eGFR) formula by Matsuo et al. 15 Follow up continued until the patients had reached an endpoint (amputation of the ischemic leg or death) or were lost to follow up. To find the prognostic factor differences, we examined patient characteristics, time to death from any cause, time to amputation of the ischemic leg or death (whichever came first) (amputation-free survival), and the primary patency period in both groups. The primary patency period was defined as the time after treatment to occlusion. Occlusion after treatment was defined as angiographic occlusion, loss of distal pulsation after treatment or worsened symptoms requiring another treatment. Hypertension, hyperlipidemia, and diabetes mellitus (DM) were defined as a systolic blood pressure of 140 mmHg or higher, a total cholesterol of 220 mg/dl and/or a LDL cholesterol of 140 mg/dl or higher, and a fasting blood glucose of 126 mg/dl or higher, respectively.
Statistical Analysis
Baseline characteristics of patients were compared using the 2-tailed t-test, or the Mann-Whitney test where appropriate, for continuous data, and the chi-square test for categorical data. Cumulative event rates were estimated with KaplanMeier survival curves, and possible statistical differences were evaluated by the log-rank test. Multiple linear regression analysis was used to determine factors affecting survival and amputation-free survival. The Cox proportional hazards model was used to obtain hazard ratios (HR) and 95% confidence intervals (CI) for overall survival and amputation-free survival. Any covariates that were significant on univariate analysis were assessed by multivariate analysis. The considered variables were as follows: age, gender, treatment methods, Fontaine classification, DM, hypertension, hyperlipidemia, smoking history, ischemic heart disease, history of dialysis, and time from dialysis start. Among the explanatory variables, qualitative variables were evaluated by a marginal method, and stepwise analysis was performed by an increasing variable method. A P value <0.05 was considered statistically significant. Data were entered and analyzed using the statistical software, JMP 8.0 (SAS Institute, Cary, NJ, USA).
Results
The baseline characteristics of the patients in each group are shown in Table 1 . Over 70% of the patients had a history of hypertension and a smoking history in each group. Approximately half of the patients had a history of DM. The percentage of CLI (Fontaine III+IV) patients was 34.1% in the HD group and 12.9% in the non-HD group, respectively (P= 0.01). There were greater numbers of older patients, patients with a history of smoking and who treated by PTA in the non-HD group than in the HD group. The mean duration of HD was 9.9±9.2 years; 9.4±9.9 years in the bypass group, and 10.7±8.5 years in the PTA group (P>0.05). The mean eGFR of non-HD patients was 67.5±25.0 ml/min in the bypass group and 63.0±20.1 ml/min in PTA group (P>0.05). The types of endovascular treatment lesions in patients with HD were: TASC A, 16%; TASC B, 38%; and TASC C, 46%; HD, history of hemodialysis; IHD, history of ischemic heart disease (angina pectoris or myocardial infarction). HOSHINO J et al.
whereas it was TASC A, 22%; TASC B, 55%; and TASC C, 23% in patients without HD. The types of surgical bypass were femoropopliteal artery bypass (57%), femoral femoral bypass (13%), Y-graft bypass (8%), axillo-femoral bypass (5%), distal bypass (5%), and others (12%). Saphenous veins were used in 13% of the patients who received femoropopliteal artery bypass. In the PTA group, 64.6% of the patients received a stent placement after the PTA procedure. Anticoagulants and/or aspirin was initiated after treatment in all patients except those with active bleeding and those needing amputation, and there was no difference in the percentage of patients who were treated with anticoagulants and/or aspirin between HD and non-HD patients, bypass and PTA groups. Figure 1A shows Kaplan-Meier survival curves of the time to amputation or death (whichever came first). Overall, amputation-free survivals at 1, 3, and 5 years were 68.3%, 53.3%, 40.0% in the HD group, and 90.9%, 84.9%, and 78.0% in the non-HD group, respectively (Figure 1A, P<0.0001).
Amputation-Free Survivals

Factors Predicting Survival and Amputation-Free Survival
Next, we determined factors affecting survival and amputation-free survival among patients who were or were not receiving HD. The significant predictors of amputation-free survival among all patients were presence of HD (HR, 2.48 [95%CI, 1.25-4.82]) and Fontaine classifications class IV Figure 1 . (A) Overall amputation-free survival after bypass surgery (bypass) and balloon angioplasty (PTA). The median amputationfree survivals for PTA and bypass groups were 2.2 years and 2.2 years, respectively. Amputation-free survival was defined as the time to amputation of the ischemic leg or death (whichever came first). (B) Overall amputation-free survival among patients who were or were not receiving dialysis (HD) in each of the bypass or PTA groups. The median amputation-free survivals for bypass-non HD, bypass-HD, PTA-non HD, PTA-HD groups were 3.0, 1.3, 2.2, 0.85 years, respectively. Characteristics of Revascularization for ASO in HD Table 2) . Both results clearly showed a poorer prognosis in HD patients than in non-HD patients. Next, we analyzed these predictors among patients who were or were not receiving HD ( Table 3 ). Among non-HD patients, the predictors for amputation-free survival were 
Therapeutic Methods (PTA and Bypass)
In the bypass group, amputation-free survivals at 1, 3, and 5 years were 79.3%, 44.3%, and 14.8% among the HD patients, and 90.1%, 84.7%, and 80.9% among the non-HD patients, respectively (Figure 1B, P=0.0002) . Overall survivals at 1, 3, and 5 years were 73.1%, 44.0% and 14.7% among the HD patients, and 95.7%, 90.2%, and 86.1% among the non-HD patients, respectively (log rank test, P<0.0001). Both amputation-free survivals and overall survivals were significantly lower in the HD patients than in the non-HD patients. In the PTA group, however, amputation-free survivals at 1, 3, 5 years were all 62.1% among the HD patients, and 91.4%, 85.1%, and 75.2% among the non-HD patients, respectively (Figure 1B, P=0.03) . Overall survivals at 1, 3, and 5 years were 74.7%, 66.5% and 66.5% among the HD patients, and 91.4%, 85.1%, and 75.2% among the non-HD patients, respectively (log rank test, P=0.18).
Primary Patency Rates
Next, we compared the primary patency rates difference in the HD patients and non-HD patients. Although there was no significant difference in the primary patency rates between PTA and bypass treatment (P=0.32) in the PTA group, the patency rates among the HD patients were significantly lower than that among the non-HD patients. In the PTA group, patency rates at 1, 3, and 5 years were 59.6%, 34.8%, and 23.2% among the HD group, and 90.4%, 75.4%, and 62.5% among the non-HD group, respectively (Figure 2A, P=0.0004 ). In the bypass group, however, primary patency rates at 1, 3, and 5 years were all 84.4% among HD patients, and 93.9%, 78.3%, and 55.2% among non-HD patients, respectively (Figure 2A, P=0.77) .
It is reported that primary patency rates are different between supra inguinal lesions and infrainguinal lesions. 15 Therefore, at first, we examined the primary patency rates of supra inguinal lesions and those of infrainguinal lesions in HD and non-HD patients. The primary patency rates of non-HD patients at 1, 3, and 5 years were 94.2%, 83.6%, and 77.1% in supra inguinal lesions, and 90.8%, 69.3%, and 41.2% in infrainguinal lesions, showing a significant difference ( Figure 2B, P=0.03) . However, the primary patency rates of HD patients at 1 and 3 years were 72.7% and 72.7% in supra inguinal lesions, and 80.4% and 49.0% in infrainguinal lesions, without showing significance (Figure 2B , P= 0.56). Then we compared the primary patency rates between the PTA and bypass groups, the patency rates in the bypass group at 1, 3, and 5 years were 96.6%, 92.2% and 79.0% in supra inguinal lesions, and 91.3%, 70.2%, and 40.1% in infrainguinal lesions, respectively (Figure 2C, P=0.03) . In contrast, the patency rates in the PTA group at 1, 3, and 5 years were 88.4%, 74.9%, and 74.9% in supra inguinal lesions, and 83.0%, 59.6%, and 38.3% in infrainguinal lesions, respectively (Figure 2C, P=0.10) . The primary patency rates of supra inguinal lesions are higher than those of infrain- Adjusted for age, history of heart disease, hypertension, and smoking history. P<0.05 was used to determine statistical significance. Abbreviations see in Tables 1,2 .
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guinal lesions in both treatments. Next, we determined factors affecting the patency rate. The significant predictor of patency period among all patients was the presence of HD (HR, 2.32 [95%CI, 1.13-4 .50], P= 0.02), which clearly showed a poorer patency rate in HD patients than in non-HD patients.
Therefore, we analyzed these predictors among patients who were or were not receiving HD ( Table 4) . Among HD patients, the predictors for patency rate were treatment method {bypass (referent, PTA) (HR, 0.18 [95%CI, 0.03-0.70], P= 0.01)} and DM (HR, 4.22 [95%CI, 1.04-21.26], P=0.04), whereas there was no significant predictor for patency rate among the non-HD patients. Thus, therapeutic selection (PTA or bypass) and presence of DM were considered to have a significant influence on the patency rate of HD patients.
In summary, in the bypass group, the patency rates were similar among patients who were or were not receiving HD (P=0.77), whereas both amputation-free survivals and overall survivals were significantly lower in the HD patients than in the non-HD patients. In contrast, in the PTA group, the primary patency rates among the HD patients were significantly lower than that among the non-HD patients.
Causes of death is shown in Table 5 . Infectious death was higher in HD patients (53%) than in non-HD patients (22%) (P<0.05).
Fontaine II Group Analysis
Next, we analyzed the outcomes of Fontaine II patients from this cohort to eliminate the ischemic condition (Fontaine classification) bias between PTA and bypass groups. The characteristics of Fontaine II patients were similar between HD and non-HD. We compared the overall survivals and amputationfree survivals in patients with Fontaine II. These survival curves were almost the same as those among all patients. In the bypass group, amputation-free survivals at 1, 3, and 5 years were 82.5%, 51.3%, and 17.1% among the HD patients, and 100%, 93.4%, and 93.4% among the non-HD patients, respectively (log rank test, P<0.0001). In the PTA group, however, the amputation-free survivals at 1, 3, and 5 years were all 76.6% among the HD patients, and 92.0%, 85.0, and 73.8% among the non-HD patients, respectively (log rank test, P=0.45). These results suggest that treatment selection peculiarly affects HD patients' amputation-free survival, independent of ischemic conditions.
Discussion
Chronic dialysis is associated with a higher prevalence of PAD. Also, a lower extremity amputation level is closely related to the patient's activity of daily living. 16 As the life expectancy is further decreased in patients on HD who are receiving PAD treatment, 17 and PAD is accompanied by diffuse vascular calcification and is involved in distal infrapopliteal and foot arteries, the treatment of PAD in HD patients has been controversial. 18 This is the first report directly showing characteristics of PAD treatments of bypass and PTA between HD and non-HD patients, giving us many suggestions even though this was a retrospective study. There were some different backgrounds of Fontaine classification in the bypass and PTA groups. However, considering the TASC criteria and that bypass surgery tends to be performed on more severe ischemic limbs, this difference should be acceptable for clinicians. Furthermore, our study clearly revealed different outcomes between HD and non-HD patients with the same ischemic conditions. We should notice that the survival and amputation-free survival after bypass surgery were significantly decreased in HD patients than in non-HD patients, in contrast to similar survival after PTA between HD and non-HD patients. This significant difference was regardless of whether the treated lesions were patented or not.
Furthermore, treatment selection and presence of DM affected survival in HD patients. We should select therapeutic methods carefully especially in DM patients who are on HD. These data suggest the importance of systemic clinical management after surgery. Because the rates of infectious complications and wound trouble in HD patients are higher than those in non-HD patients, team management involving cardiovascular surgeons, nephrologists, and infectious control teams is needed to achieve better patient survival, especially for HD patients.
Hyperlipidemia is considered as one of the risk factors for PAD patients, 19 and statins could reduce this risk. 20, 21 In our study, the presence of hyperlipidemia brought better outcomes especially in non-HD patients. This different outcome might be because of a significantly higher rate of administration of statins in patients with hyperlipidemia.
In our study, the patency rates between patients with and without HD in the bypass group did not show a significant difference. However, the patient backgrounds of bypass types between these 2 groups are not equal. The percentage of HD patients who received Y-graft, femoral femoral bypass, and femoropopliteal artery bypass was smaller than that of non-HD patients (P<0.01), even though the number of patients was relatively small. It is reported that 5-year patency estimates are higher in patients who received Y-graft, femoral femoral bypass, and femoropopliteal bypass than patients who received other bypass methods. 14 Therefore, the graft patency rate of HD patients might be different if we could compare patients with the same backgrounds.
It is important to consider operator bias and therapeutic selection bias (the criteria by which bypass or PTA is chosen) when analyzing the outcomes of PAD patients. In most reports, PAD patients on HD who underwent bypass or PTA were treated by different surgeons, cardiovascular physicians, wound care physicians, and nephrologists, which might result in dissimilar quality of care and is a study limitation. Furthermore, in multicenter studies, there might be therapeutic selection bias in each hospital if there are no strict criteria for treatment selection. In contrast, this study was performed at a single general hospital with the same surgeons, cardiovascular physicians, and nephrologists, which could exclude these limitations.
Our results showed better outcomes in both patients who 
